Saudi outlet Hadas reports Trump has invited Iraq's prime minister to visit the White House in mid-July.

JP Morgan upgraded Hengrui Medicine (01276.HK) from Hold to Overweight and trimmed its target price to HK$68 from HK$70. The bank said the sharp share-price decline reflects macro headwinds—notably heightened U.S.-China geopolitical tensions and broad institutional de-risking of H-share healthcare—rather than a material weakening of fundamentals. At current levels, JP Morgan sees valuation as understating an improving earnings trajectory, rapidly expanding pipeline value and BD-related revenue, but warned U.S. rules could constrain future China-origin licensing deals and increase volatility.

欧洲投资银行行长：将于本月晚些时候与一家欧洲大型国防企业签署一项数额巨大的协议。